Clinical Trials Logo

Uterine Hemorrhage clinical trials

View clinical trials related to Uterine Hemorrhage.

Filter by:

NCT ID: NCT06067217 Recruiting - Clinical trials for Abnormal Uterine Bleeding

Comparative Study of Tranexamic Acid, Estrogen for Treatment AUB in DMPA Users

Start date: September 30, 2023
Phase: N/A
Study type: Interventional

Abnormal uterine bleeding is the most common problems to discontinue Depo-medroxyprogesterone acetate (DMPA) in Thailand. This clinical trial use to provide drug to stop abnormal uterine bleeding from DMPA

NCT ID: NCT06050161 Not yet recruiting - Clinical trials for Pelvic Organ Prolapse

Evaluating Artisential Laparoscopic Instruments in Gynecologic Surgery

MIGS-ART
Start date: September 20, 2023
Phase: N/A
Study type: Interventional

This study evaluates the efficacy and safety of Artisential laparoscopic instruments in minimally invasive gynecologic surgery.

NCT ID: NCT06024109 Recruiting - Ovarian Cancer Clinical Trials

Performance of SYMMCORA® vs. V-Loc® Suture Material in Patients Undergoing Laparoscopic Total Hysterectomy

BARHYSTER
Start date: March 19, 2024
Phase:
Study type: Observational

The aim of this study is to show the superiority of the new unidirectional barbed suture (SYMMCORA® mid-term, unidirectional) to conventional suture material in terms of time to perform the vaginal cuff closure during gynecologic surgeries without an increase in the complication rate. Secondly, the superiority of SYMMCORA®, mid-term unidirectional compared to the V-Loc®, unidirectional will be assessed regarding the mean time to close the vaginal cuff. The study will be performed in routine clinical setting, the only difference will be the randomization into two different suture groups. Both suture materials which will be applied to approximate the vaginal cuff are approved and carrying the CE-marks. Additionally, both sutures will be applied in their intended use. Neither additional invasive measures nor additional burden in regard to the patient will be performed.

NCT ID: NCT06004908 Not yet recruiting - Clinical trials for Postmenopausal Bleeding

Role of MRI in Diagnosis of Postmenopausal Bleeding Causes

Start date: October 1, 2023
Phase:
Study type: Observational

The aim of the study is to determine the diagnostic performance of MRI of endometrial pathology in postmenopausal women with postmenopausal bleeding

NCT ID: NCT05996926 Not yet recruiting - Clinical trials for Cesarean Section Complications

Diagnostic Accuracy of Saline Sonohystrography vs. 3D Transvaginal Ultrasound for Cesarean Scar Defect Assessment

Start date: August 30, 2023
Phase: N/A
Study type: Interventional

To compare accuracy of three dimensional transvaginal ultrasound versus the "gold standard" saline infused sonography for assessing the characteristics, frequency and appearance of caesarean scar defects in symptomatic patients with a history of cesarean section.

NCT ID: NCT05922657 Recruiting - Menorrhagia Clinical Trials

A Registry to Gather Real World Use Data on the Cerene® Cryotherapy Device

Progress
Start date: June 9, 2023
Phase:
Study type: Observational [Patient Registry]

Channel Medsystems, Inc., the manufacturer of the Cerene® Cryotherapy Device (Cerene), is initiating a prospective, observational registry, the Progress registry, to gather data during real world utilization of the Cerene® Cryotherapy Device (Cerene). The primary objective of this registry is to bridge the gap between clinical results and outcomes achieved and reported during the pivotal study of Cerene and those obtained during its real-world use.

NCT ID: NCT05840471 Completed - Vaginal Bleeding Clinical Trials

Tranexamic Acid as an Intervention in Abruptio Placenta

Start date: January 10, 2023
Phase: N/A
Study type: Interventional

Abruptio placenta is one of the common causes of antepartum haemorrhage which is more common in the second half of pregnancy and causes a high maternal and neonatal morbidity and mortality

NCT ID: NCT05783479 Completed - Uterine Bleeding Clinical Trials

Pharmacological Preparation of the Cervix for Hysteroscopy

Start date: June 1, 2022
Phase: N/A
Study type: Interventional

Pain accompanying office hysteroscopy is the most common reason for its discontinuation. Urogenital atrophy may cause technical difficulties in passage through the cervical canal, further increasing the pain. The aim was to evaluate the effectiveness of vaginal estradiol and hyaluronic acid to facilitate diagnostic hysteroscopy in peri- and postmenopausal women.

NCT ID: NCT05668806 Completed - Vaginal Bleeding Clinical Trials

RWE Study in the Treatment of Cervical Lesions of Various Etiology

Start date: May 20, 2021
Phase:
Study type: Observational

The aim of the study was to assess the post-market performance and tolerability of Cerviron® ovules in the treatment and management of cervical lesions of different etiologies. The study included clinical data related to aspect of lesions performed during routine colposcopy exams, the degree of re-epithelialization of the cervical mucosa, vaginal pH, pain level, and vaginal bleeding level.

NCT ID: NCT05661708 Completed - Vaginal Bleeding Clinical Trials

Use of Chitosan Powder in Loop Electrosurgical Excision Procedure

Start date: December 15, 2022
Phase: Phase 4
Study type: Interventional

Early treatment of cervical intraepithelial neoplasia (CIN) II-III gives rise to a decrease in the incidence of invasive cervical cancer. Though there is no obvious consensus from randomized studies as to the optimal management of CIN II-III, loop electrosurgical excision procedure (LEEP) is the most extensively used method because of its technical ease, inexpensive, steep learning curve, and low rate of complications. In spite of these benefits, current literature suggests that some patients experience some complications such as postoperative vaginal bleeding, abnormal vaginal discharge, abdominal pain, and infection. These adversely affect the recovery period, increase patient anxiety, readmission to the hospital for further treatment and encumber patients' daily life. Postoperative vaginal bleeding (PVB) is one of the most common and unpleasant of these complications. Its incidence has been reported to vary between 2% to 78%. Many different types of treatments have been applied to avert or diminish PVC such as the use of vasopressin, tranexamic acid, Monsel's solution, and local hemostats (e.g., TachoSil or Tisseel), but these attempts have failed to show precise benefits over routine clinical approaches. Chitosan is a biodegradable, natural polyaminosaccharide with a nontoxic, non-allergenic, positively-charged polysaccharide derived from the deacetylation of chitin. Due to its molecular characteristics, chitosan has been used for improved hemostasis. Furthermore, chitosan has an antimicrobial and wound-healing effect. The current literature concerning the influence of using chitosan after the LEEP is limited to only one trial. The authors of that study reported that using chitosan after the LEEP can reduce vaginal bleeding and enhancing wound healing. However, that study has some limitations. Therefore, investigators designed this randomized trial to assess the effect of local chitosan implementation on postoperative vaginal bleeding and wound healing in LEEP